MDMA-assisted therapy

Biopharma company Atai Life Sciences (NASDAQ: ATAI) shared positive results from a Phase 1 clinical study on MDMA R-enantiomer, EMP-01, under development for the potential treatment of PTSD. Assessing EMP-01's safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD...

The for-profit arm of the legendary Multidisciplinary Association for Psychedelic Studies, MAPS Public Benefit Corporation (MAPS PBC), has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for MDMA (midomafetamine capsules) paired with...

Canadian not-for-profit organization TheraPsil has received board approval to launch its training program on MDMA-assisted psychotherapy for trauma survivors. TheraPsil has been advancing legal access to psychedelic-assisted psychotherapy since 2019. The new course, which joins the...

The long-awaited psychedelic-assisted treatment alternative for Post-Traumatic Stress Disorder (PTSD) is moving closer to federal approval.  The Multidisciplinary Association for Psychedelic Studies (MAPS) and its private subsidiary company, MAPS PBC shared the publication of the...

MAPS Public Benefit Corporation (MAPS PBC), the nonprofit’s clinical-stage private arm, published new data from its second multi-site, ethno-racially diverse Phase 3 clinical study of MDMA-assisted therapy for PTSD in Nature Medicine.  The randomized MAPP2 study gave participants a split...

Psychedelic therapy training company Fluence is partnering with Brazil-based nonprofit research organization Phaneros Institute. Fluence will grant Phaneros access to its educational content through its online learning management system. An additional Brazilian Portuguese-translated version of the...

Numinus Wellness (OTCMKTS: NUMIF) with support from the Multidisciplinary Association for Psychedelic Studies (MAPS) will utilize Optimi Health’s (OTCMKTS: OPTHF) Good Manufacturing Practice (GMP)-compliant MDMA to conduct a therapist-experiential training program.  See...

In a prelude to what is hoped will be regulatory approval of MDMA-assisted therapy in the U.S. and Canada, Numinus Wellness Inc. (OTC: NUMIF) has taken steps to get out in front of the curve. Today, the company has announced a partnership with the Multidisciplinary...

The FDA has approved a clinical trial that will assess PharmAla Biotech Holdings' (OTC: PMBHF) proprietary LaNeo Investigational Medical Product (IMP) 40mg MDMA capsules for the treatment of schizophrenia. This is the first time these capsules will be tried on humans in the U.S...

Australia-based cannabis and psychedelics company Creso Pharma Ltd. (OTCMKTS: COPHF) inked a Letter of Intent (LOI) with Swiss pharmacy Apotheke Dr. Hysek AG toward an exclusive partnership for the import and distribution of licensed MDMA and psilocybin products into Australia, of which...

In the current psychedelics landscape, one of the most important topics is compound legality.  While it's possible that MDMA-assisted therapy will eventually be federally approved in the U.S., what should investors consider when looking at a prospective business? The 2023 edition of...

MDXX-class molecules producer PharmAla Biotech Holdings Inc. and natural psychedelics developer Filament Health Corp's (OTCQB: FLHLF) partnership is seeing the release of GMP-compliant MDMA capsules for distribution to clinical trials and authorized patients in Canada and worldwide....

Specialty drug delivery technology biopharma company Revive Therapeutics Ltd. (OTCQB: RVVTF) is undertaking research and development activities for its proprietary transdermal microneedle patch to deliver MDMA toward IND-enabling studies, supported by an exclusive supply deal with PharmaAla Biotech...

PharmAla To Be Exclusive MDMA Supply Partner To Awakn Life Sciences Effective immediately, MDXX class molecules producer PharmAla Biotech Holdings Inc. will become the exclusive MDMA supplier to Awakn Life Sciences (OTCMKTS: AWKNF). “We’ve been working with the Awakn team...

As of July 1, psilocybin and MDMA (and related substances to both) can now be prescribed by authorized psychiatrists in Australia, which has become the fourth government agency to enact a compassionate use program for psychedelic-assisted therapies to treat mental health conditions joining Israel,...